Filing Flows › NRX Pharmaceuticals (NRXP) › Q2 2026
NRX Pharmaceuticals (NRXP) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
NRX Pharmaceuticals (NRXP) reported revenue of $1.1M for the second quarter 2026 (Q2 2026) and +3% from the quarter before. Operating margin was -590.8%.
NRX Pharmaceuticals, Q2 2026: revenue $1.1M, operating margin -590.8%, net loss $16.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +3% | — |
| Operating profit | −$6.5M | — | — |
| Net earnings | −$16.5M | — | — |
| Operating cash flow | −$8.9M | — | — |
What changed
Revenue was $1.1M in Q2 2026, up 3% from the previous quarter. Therapy was the largest line at 79% of revenue.
Operating costs exceeded revenue by $6.5M, an operating margin of -590.8%. The quarter ended with a net loss of $16.5M, wider than the previous quarter's $1.4M loss. Net interest and other expense of $10.0M was the main reason.
Operating cash flow was −$8.9M. Non-cash charges added back $71K of depreciation and amortization and $139K of share-based compensation. Working capital and other items added $7.4M.
Questions
What was NRX Pharmaceuticals' revenue in the second quarter 2026?
NRX Pharmaceuticals (NRXP) reported revenue of $1.1M for the second quarter 2026 (Q2 2026) and +3% from the quarter before.
Was NRX Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $6.5M (-590.8% of revenue) and net loss $16.5M.